Patent assignee · US · COMPANY

Stemcentrx, Inc.

19Patents
18Active
19Granted
49Portfolio score

Filing activity: Sep 2, 2011 → Jan 25, 2016

Most-cited patents

PatentTitleAreaCited byStatus
US9089615B2 Anti-DLL3 antibodies Physics 16 Active
US8986972B2 Nucleic acid encoding DLL3 antibodies Physics 16 Active
US9089617B2 Anti-DLL3 antibody drug conjugates Physics 9 Active
US9090683B2 Methods of detection, diagnosis, and monitoring using anti-DLL3 antibodies Physics 8 Active
US9358304B1 Methods of making DLL3 antibody drug conjugates Physics 8 Active
US9133271B1 Anti-DLL3 antibody drug conjugates and methods of use Physics 8 Active
US9089616B2 Anti-DLL3 antibody drug conjugates and methods of use Physics 8 Active
US9352051B1 Kits containing DLL3 antibody drug conjugates Physics 8 Active
US9155803B1 Anti-DLL3 antibody drug conjugates and methods of use Physics 8 Active
US9334318B1 Multivalent DLL3 antibodies Physics 8 Active
US9353182B2 Anti-DLL3 antibodies Physics 8 Active
US9409995B2 PTK7 modulators and methods of use Chemistry; Metallurgy 8 Active
US9107961B2 Anti-DLL3 antibody drug conjugates for treating cancer Physics 8 Active
US9320812B2 Modulators and methods of use Chemistry; Metallurgy 6 Active
US9458231B2 Modulators and methods of use Chemistry; Metallurgy 3 Active
US9173959B1 Anti-DLL3 antibody drug conjugates Physics 3 Active
US9345784B1 Methods of delivering DLL3 antibody drug conjugates Physics 3 Active
US9011854B2 Anti-DLL3 antibody drug conjugates and methods of use General 0 Revoked
US9381205B2 Anti-EFNA4 antibody-drug conjugates Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.